<?xml version="1.0" encoding="UTF-8"?>
<document id="28655712">
	<sentence id="s1" text="Alterations in li>MEK1/2</i> occur in cancers, both in the treatment-naÃ¯ve state and following targeted therapies, most notably BRAF and MEK inhibitors in li>BRAF</i>-V600E-mutant melanoma and colorectal cancer.">
		<entity id="s1.e1" charOffset="38-44"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e2" charOffset="128-132"
			type="GENE" text="BRAF" ontology_id="673"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="true"/>
	</sentence>
	<sentence id="s2" text="This work highlights the importance of classifying mutations based on structural and phenotypic consequences, both in terms of pathway signaling output and response to pharmacologic inhibition.<b>Implications:</b> This study suggests that alternate modes of target inhibition, such as ERK inhibition, will be required to effectively treat tumors harboring these MEK1/2-resistant alleles.">
		<entity id="s2.e1" charOffset="285-288"
			type="GENE" text="ERK" ontology_id="2048"/>
		<entity id="s2.e2" charOffset="339-345"
			type="HP" text="tumors" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
</document>
